肠道菌群代谢物咪唑丙酸可预测冠心病患者的心血管代谢风险
在多个独立前瞻性队列(ACS与CCS患者)中测量循环咪唑丙酸(ImP)水平,发现其与更严重的CAD及糖尿病、高敏C反应蛋白升高相关,且独立预测MACE和死亡,预测价值超越TMAO。
要点
- 高ImP是CAD患者MACE和死亡的独立预测因子。
- ImP的预测价值独立于传统危险因素及TMAO。
- ImP或可用于优化CAD患者二级预防的风险分层。
核心结论
- 肠道菌群来源的ImP独立于传统危险因素预测CAD患者的MACE,有潜力作为治疗靶点并优化风险分层。
研究设计与样本
- 在急性冠脉综合征(ACS)和慢性冠脉综合征(CCS)的独立前瞻性队列中测量循环ImP水平,包括瑞士ACS队列n=4787、瑞士心脏磁共振队列n=150、德国ACS队列n=1428和德国CCS队列n=701。
主要发现
- 循环ImP与更晚期CAD及心脏代谢特征(包括糖尿病和高敏C反应蛋白升高)相关。
- 高ImP独立预测MACE:瑞士ACS队列每log2增加HR 1.22(95%CI 1.10-1.35,P<.001);德国ACS队列HR 2.34(95%CI 1.46-3.76,P<.001);德国CCS队列HR 1.32(95%CI 1.13-1.53,P<.001)。
- 高ImP独立预测死亡:瑞士ACS队列HR 1.34(95%CI 1.17-1.54,P<.001);德国ACS队列HR 2.38(95%CI 1.48-3.82,P<.001);德国CCS队列HR 1.50(95%CI 1.14-1.98,P=.004)。
- ImP提供超越TMAO的预测价值:瑞士ACS队列HR 1.30(95%CI 1.05-1.61,P=.014);德国CCS队列HR 1.31(95%CI 1.12-1.53,P=.001)。
临床怎么用
- 对于CAD患者,可考虑检测循环ImP水平以辅助风险分层,识别高危患者进行更积极的二级预防。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The gut microbiota is a modulator of cardiometabolic disease. Circulating imidazole propionate (ImP) is a microbiota-derived proatherogenic amino acid metabolite modulating the inflammatory response of myeloid cells, endothelial function, and glucose metabolism. This study examined the prognostic value of ImP in patients with coronary artery disease (CAD). METHODS: Circulating ImP levels were measured in independent prospective cohorts of patients with acute coronary syndrome (ACS; Swiss ACS cohort n = 4787, Swiss cardiac magnetic resonance imaging cohort n = 150, German ACS cohort n = 1428) and chronic coronary syndrome (CCS; German CCS cohort n = 701). Major adverse cardiovascular events (MACE), defined as the first occurrence of a composite of death, non-fatal myocardial infarction, or non-fatal stroke after admission, were the primary endpoint. Cox models, accounting for established risk factors including the gut-derived cardiovascular risk factor trimethylamine N-oxide, were used to evaluate the predictive value of ImP. RESULTS: Circulating ImP was associated with more advanced CAD and with cardiometabolic characteristics including diabetes and elevated high-sensitivity C-reactive protein. High ImP was an independent predictor of MACE [Swiss ACS cohort: hazard ratio (HR) per log2 increase 1.22, 95% confidence interval (CI) 1.10-1.35, P < .001; German ACS cohort: HR 2.34, 95% CI 1.46-3.76, P < .001; German CCS cohort: HR 1.32, 95% CI 1.13-1.53, P < .001)] and of mortality (Swiss ACS cohort: HR 1.34, 95% CI 1.17-1.54, P < .001; German ACS cohort: HR 2.38, 95% CI 1.48-3.82, P < .001; German CCS cohort: HR 1.50, 95% CI 1.14-1.98, P = .004) after adjustment for established risk factors. Imidazole propionate provided predictive value beyond trimethylamine N-oxide (Swiss ACS cohort: HR 1.30, 95% CI 1.05-1.61, P = .014; German CCS cohort: HR 1.31, 95% CI 1.12-1.53, P = .001). CONCLUSIONS: Gut microbiota-derived ImP predicted MACE in patients with CAD independently of traditional risk factors and holds promise as a therapeutic target. Imidazole propionate may refine risk stratification for personalized secondary prevention strategies.
引用
- Wenzl FA, Wang P, Kahles F, et al. Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease. Eur Heart J. 2026. PMID: 40884168. doi:10.1093/eurheartj/ehaf661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。